Takeda Pharmaceutical has received FDA approval for three new treatments for type 2 diabetes - NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl).
Category: Products & Tech
I am able to wear the CGM places other than my abdomen, which I was terrified to even try with the Minimed. Thus far, I have worn the Dexcom on my lower back (worked all right, but sub-optimally; it was prone to getting knocked and jostled off) and my arm (works capitally). This ability to move the sensor around opens up my abdomen, which was getting bruised and scarred to the point of not being usable.
The European Commission has granted Novo Nordisk marketing authorizations for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes in adults in 27 European Union member states.
New research from the University of Pennsylvania has discovered that the most popular type 2 diabetes medication, metformin, works differently than previously thought. Metformin was known to lower blood glucose levels by decreasing the amount of glucose produced by the liver, but how the drug did this was not known.
Not all of the diabetes products that we expected to be available in 2012 made it to market, but we hope that some of them will be approved in 2013 and will soon after be available in the U.S. Here are some of the diabetes products we're hoping to have in 2013
The Japanese Ministry of Health, Labor and Welfare has approved Novo Nordisk's new combination insulin, Ryzodeg, for the treatment of diabetes.
Ryzodeg is a soluble formulation of Tresiba (insulin degludec), a once-daily new-generation basal insulin analogue with an ultra-long duration of action, and NovoRapid (insulin aspart which in the U.S. is marketed under the brand name NovoLog). Ryzodeg can be administered once or twice daily with the main meal(s).
Insulet Corporation, the leader in tubeless insulin pump technology, today announced that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the next-generation OmniPod® Insulin Management System.
The Dario glucose meter is an integrated unit that includes an adapter designed to connect to the audio jack of a smartphone. When the adapter is connected, a measurement is transmitted to the smartphone, turning the phone into a glucose monitor. The Dario also includes a built in lancing device loaded with disposable lancets and an integrated cartridge holding and dispensing 25 test strips.
My diabesties, as we began to call ourselves, were also struggling to manage diabetes in college. The three of us agreed that it was time to take responsibility and to hold each other and ourselves accountable for living healthy lives with diabetes. There was no reason for us to spend so much time feeling guilty, tired, frustrated, and sick.
The European Commission has approved Bristol-Myers Squibb and AstraZeneca's new type 2 diabetes therapy, Forxiga (dapagliflozin), for use in the European Union (EU).
Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body